Alteration of the fecal microbiota in Chinese patients with Parkinson's diseaseOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This case-control study examined the fecal microbiota composition of patients with Parkinson's disease (PD) in a Chinese cohort. Researchers used high-throughput Illumina Miseq sequencing targeting the V3-V4 region of the 16S ribosomal RNA gene to profile bacterial communities. The study aimed to characterize gut microbiota dysbiosis in Chinese PD patients, a population not previously examined for this question, and to relate microbiota features to clinical characteristics of the disease.
Who was studied?
The study included 45 patients with Parkinson's disease and their healthy spouses, who served as controls. Using spouses as controls helps account for shared household diet and environment. Clinical characteristics analyzed alongside the microbiota data included age, gender, body mass index (BMI), constipation status, disease duration, levodopa equivalent dose (LED), and non-motor symptoms such as cognitive impairment.
What were the most important findings?
The structure and richness of the fecal microbiota differed between PD patients and healthy controls. After adjusting for age, gender, BMI, and constipation, the genera Clostridium IV, Aquabacterium, Holdemania, Sphingomonas, Clostridium XVIII, Butyricicoccus, and Anaerotruncus were enriched in PD patients. Escherichia/Shigella were negatively associated with disease duration, Dorea and Phascolarctobacterium were negatively associated with levodopa equivalent dose, and Butyricicoccus and Clostridium XlVb were associated with cognitive impairment. The abstract does not mention Desulfovibrio, sulfate-reducing bacteria, hydrogen sulfide, or sulfur metabolism.
What are the greatest implications of this study?
The findings confirm that gut microbiota dysbiosis occurs in Chinese patients with Parkinson's disease, extending prior evidence from other populations. The associations between specific genera and disease duration, medication dosing, and cognitive symptoms suggest the microbiome may track with clinical progression and treatment response rather than being a static feature. These patterns support further investigation of fecal microbiota as a potential biomarker or contributor to PD's motor and non-motor manifestations.